PFIZER INC Goodwill, Foreign Currency Translation Gain (Loss)
PFIZER INC (PFE) reported Goodwill, Foreign Currency Translation Gain (Loss) of $574.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2026-02-26
- PFIZER INC goodwill, foreign currency translation gain (loss) for the quarter ending 2024-12-31 was -$403.00M.
- PFIZER INC goodwill, foreign currency translation gain (loss) for the quarter ending 2024-09-29 was $141.00M.
- PFIZER INC goodwill, foreign currency translation gain (loss) for the quarter ending 2024-06-30 was -$6.00M.
- PFIZER INC goodwill, foreign currency translation gain (loss) for the quarter ending 2024-03-31 was -$10.00M.
- PFIZER INC goodwill, foreign currency translation gain (loss) for fiscal 2025 was $574.00M.
- PFIZER INC goodwill, foreign currency translation gain (loss) for fiscal 2024 was -$278.00M, a 195.21% decline from fiscal 2023.
- PFIZER INC goodwill, foreign currency translation gain (loss) for fiscal 2023 was $292.00M.
- PFIZER INC goodwill, foreign currency translation gain (loss) for fiscal 2022 was -$750.00M.
| Period end | Goodwill, Foreign Currency Translation Gain (Loss) 3 month | Goodwill, Foreign Currency Translation Gain (Loss) 6 month | Goodwill, Foreign Currency Translation Gain (Loss) 9 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $574.00M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | -$403.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$262.00M derived: sum of 2 quarters · filed 2026-02-26 | -$268.00M derived: sum of 3 quarters · filed 2026-02-26 | -$278.00M 10-K · filed 2026-02-26 |
| 2024-09-29 | $141.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $135.00M derived: sum of 2 quarters · filed 2024-11-04 | $125.00M 10-Q · filed 2024-11-04 | |
| 2024-06-30 | -$6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$16.00M 10-Q · filed 2024-08-05 | ||
| 2024-03-31 | -$10.00M 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $292.00M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$400.00M derived: sum of 2 quarters · filed 2024-02-22 | -$729.00M derived: sum of 3 quarters · filed 2024-02-22 | -$750.00M 10-K · filed 2024-02-22 |
| 2022-10-02 | -$447.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$776.00M derived: sum of 2 quarters · filed 2022-11-09 | -$797.00M 10-Q · filed 2022-11-09 | |
| 2022-07-03 | -$329.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$350.00M 10-Q · filed 2022-08-10 | ||
| 2022-04-03 | -$21.00M 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | -$348.00M 10-K · filed 2023-02-23 | |||
| 2020-12-31 | $126.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $648.00M 10-K · filed 2022-02-24 | ||
| 2020-09-27 | $522.00M 10-Q · filed 2020-11-05 | |||
| 2019-12-31 | -$136.00M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |